Cengiz TUĞLU, Sevilay ÖZCAN, Yasin ERDOĞAN, Nejdet SÜT, MEHMET ERDAL VARDAR, ERCAN ABAY

The relation of homocysteine levels with deficit syndrome and working memory in schizophrenic patients

Şizofreni hastalarında homosistein düzeyinin eksiklik sendromu ve çalışma belleği ile ilişkisi

Objective: There are many theories about etiology of schizophrenia and many studies are going on to find out a biologic determinant specific for schizophrenia. Single carbon metabolism theory has been suggested for the etiology of schizophrenia. There are also many data about a defect in homocysteine metabolism and increased levels of homocysteine in schizophrenic subjects but the correlation of hyperhomocysteinemia with the clinical reflections and symptom dispersion of schizophrenia has not been studied yet. Methods: For forty-one schizophrenic patients, clinical assessments were performed. The patients were divided into two groups, as deficit syndrome group and nondeficit syndrome group, using the deficit syndrome chart. Various test batteries have been applied to all patients to asses the clinical symptomatology and working memory. Serum homocysteine, vitamin B12, and folic acid levels were measured concurrently. Results: Homocysteine levels were higher in the study group and mild to moderate hyperhomocysteinemia has been observed at the sample group independent folic acid levels. The homocysteine levels and clinical scale scores did not correlate statistically but folic acid levels did with negative symptomotology and functional disturbance. Conclusion: Serum homocysteine levels were elevated in both male and female schizophrenia patients. Hyperhomocysteinemia with the deficit syndrome as well as working memory did not show a statistically significant correlation. (Anatolian Journal of Psychiatry 2011; 12:169-176)

PDF

___

1. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363:263-271.

2. Sadock BJ, Sadock VA. Kaplan and Saddock’s Synopsis of Psychiatry, ninth ed., Philadelphia, Lippincott Williams and Wilkins, 2003, p.471-504.

3. Rapoport JL, Addington AM, Frangou S. The Neurodevelopmental model of schizophrenia: update. Mol Psychiatry 2005; 10:434-449.

4. Ashe PC, Berry MD, Boulton AA. Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. Prog Neuropsychopharmacol & Biol Psychiatry 2001; 55:691-707.

5. Castner SA, Goldman-Rakic PS, Williams GV. Animal models of working memory: insights for targeting cognitive disfunction in schizophrenia. Psychopharmacology 2004; 174:111-125.

6. Lee J, Park S. Working memory impairments in schizophrenia: A meta analysis. J Abnorm Psychol 2005; 114:599-611.

7. Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 2005; 10:27-39.

8. Cameron AM, Oram J, Geffen GM, Kavanagh DJ, McGraft JJ, Geffen LB. Working memory correlates of three symptom clusters in schizophrenia. Psychiatry Res 2002; 110:49-61.

9. Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry 2004; 19:21-26.

10. Ceylan ME, Çetin M. Araştırma ve kinik uygulamalarda biyolojik psikiyatri. Şizofreni, cilt 1-2, üçüncü baskı, İstanbul, Yer Küre, 2005, s.83-85,1444-1445.

11. Çıtak S, Oral ET, Aker AT, Şenocak M. Şizofrenide eksiklik sendromu çizelgesi (ESÇ)’nin güvenilirlik ve geçerlilik çalışması. Türk Psikiyatri Dergisi 2006; 17:115-128.

12. Amador XF, Kirkpatrick B, Buchanan RW, Carpenter WT, Marcinka L, Yale SA. Stability of the diagnosis of deficit syndrome in schizophrenia. Am J Psychiatry 1999; 156:637-639.

13. Galderisi S, Maj M, Mucci A, Cassano GB, Invernizzi G, Rossi A Vita A, et al. Historical, psychopthological, neurological and neuropsychological aspects of deficit schizophrenia: A multicenter study. Am J Psychiatry 2002; 159:983-990.

14. Pesold C, Roberts RC, Kirkpatrick B. Neuroscience of schizophrenia. J Panksepp (Ed.), Textbook of Biological Psychiatry, New Jersey, Wiley-Liss, 2004, p.267-294.

15. Mohamed S, Paulsen JS, O’Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia. Arch Gen Psychiatry 1999; 56:749-754.

16. Kuperberg G, Heckers S. Schizophrenia and cognitive function. Curr Opin Neurobiol 2000; 10:205-210.

17. Dickinson D, Iannone VN, Wilk CM, Gold JM. General and specific cognitive deficits in schizophrenia. Biol Psychiatry 2004; 55:826-833.

18. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000; 14:1-21.

19. Ertuğrul A, Rezaki M. Prefrontal korteks ve şizofreni. Klinik Psikofarmakoloji Bülteni 2006; 16:118-127.

20. Perlstein WM, Carter CS, Noll DC, Cohen JD. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry 2001; 158:1105-1113.

21. Ünal S. Şizofrenide bilişsel işlev bozuklukları ve belirti oluşumu ile ilişkisi. Anadolu Psikiyatri Derg 2003; 4:46-53.

22. Keri S, Janka Z. Critical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia. Acta Psychiatr Scand 2004; 110:83-91.

23. Silver H, Feldman P, Bilker W, Gur RC. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry 2003; 160:1809-1816.

24. Başoğlu C, Ateş MA, Algül A, İpçioğlu OM, Geçici Ö, Yılmaz O, et al. Major depresif bozukluğu olan hastalarda essitaloprama folik asit ekleme tedavisi ve homosistein, folik asit, B-12 vitamini düzeyleri. Klinik Psikofarmakoloji Bülteni 2009; 19:135-142.

25. Levine J, Timinsky I, Vishne T, Dwolatzky T, Roitman S, Kaplan Z, et al. Elevated serum homocysteine levels in male patients with PTSD. Depress Anxiety 2008; 25:154-157.

26. Frankenburg FR. The role of one-carbon metabolism in schizophrenia and depression. Harv Rev Psychiatr 2007; 15:146-160.

27. Troen AM. The central nervous system in animal models of hiperhomocysteinemia. Prog Neuropsychopharmacol and Biol Psychiatry 2005; 29:1140-1151.

28. Rosenquist TH, Schneider AM, Monaghan DT. Nmethyl-D-aspartate receptor agonists modulate homocysteine induced developmental abnormalities. FASEB J 1999; 13:1523-1531.

29. Reynolds EH. Benefits and risk of folic acid to the nervous system. J Neurology Neurosurg Psychiatry 2002; 72:567-571.

30. Özsoy S, İzgi HB, Eşel E, Turan T, Baştürk M, Sofuoğlu S. Şizofreni, bipolar bozukluk ve major depresif bozukluk hastalarında farmakoterapinin vitamin B12 ve folik asit düzeylerine etkileri. Klinik Psikofarmakoloji Bülteni 2009; 19:128-134.

31. Brown AS, Susser ES. Homocysteine and schizophrenia: from prenatal to adult life. Prog Neuropsychopharmacol & Biol Psychiatry 2005; 29:1175-1180.

32. Andreasen NC. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 1990; 24:73-88.

33. Erkoç Ş, Arkonaç O, Ataklı C, Özmen E. Pozitif semptomları değerlendirme ölçeğinin güvenilirliği ve geçerliliği. Düşünen Adam 1991; 4:20-24.

34. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 1989; 7:49-58.

35. Erkoç Ş, Arkonaç O, Ataklı C, Özmen E. Negatif semptomları değerlendirme ölçeğinin geçerliliği ve güvenilirliği. Düşünen Adam 1991; 4:16-19.

36. Köroğlu E (Editör). DSM-IV-TR Tanı Ölçütleri Başvuru Kitabı. Ankara, Hekimler Yayın Birliği, 2001, s.39-42,137-141.

37. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT. The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989; 30:119-123.

38. Brown J. Some Tests of the decay of immediate memory. Quarterly Journal of Experimental Psychology 1958; 10:12-21.

39. Anıl AE, Kıvırcık BB, Batur S, Kabakçı E, Kitiş A, Güven E, et al. The Turkish version of auditory consonant trigram test as a measure of working memory: A normative study. Clin Neuropsychol 2003; 17:159-169.

40. Stahl Z, Belmaker RH, Friger M, Levine J. Nutritional and life style determinants ofplasma homocysteine in schizophrenia patients. Eur Neuropsychopharmacol 2005; 15:291-295.

41. Applebaum J, Shimon H, Sela BA, Belmaker RH, Levine J. Homocysteine levels in newly admitted schizophrenic patients. J Psychiatr Res 2004; 38:413-416.

42. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker RH. Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 2002; 159:1790-1792.

43. Virgos C, Martorell L, Simo JM, Valero J, Figuera L, Joven J, et al. Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. Neuroprot 1999; 13:2035-2038.

44. Reif A, Schneider MF, Kamolz S, Pfuhlmann B. Homocysteinemia in psychiatric disorders: associations with dementia and depression but not schizophrenia in female patients. J Neural Transm 2003; 110:1401-1411.

45. Petronijevic ND, Radonjic NV, Ivkovic MD, Marinkovic D, Piperski VD, Duricic BM, et al. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1921-1926.

46. Haidemenos A, Kontis D, Gazi A, Kallai E, Allin M, Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1289-1296.

47. Ma YY, Shek CC, Wong MC, Yip KC, Ng RM, Nguyen DG, et al. Homocysteine level in schizophrenia patients. Aust N Z J Psychiatry 2009; 43:760-765.

48. Bleich S, Kornhuber J. Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 2003; 60:1220-1255.

49. Sachdev PS, Valenzuela M, Wang XL, Looi JC, Brodaty H. Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 2002; 58:1539-1541.

50. Arioğlu S, Cankurtaran M, Dağlı N, Yavuz B. Vitamin B12, folat, homocysteine and dementia: are they really related? Arch Gerontol Geriatr 2005; 40:139-146.

51. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, et al. Folate homocysteine and negative symptoms in schizophrenia. Am J Psychiatry 2004; 161:1705-1708.

52. Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, et al. Homocysteine reducing strategies improve symptoms in chronic schizophrenic patients with hiperhomocysteinemia. Biol Psychiatry 2006; 60:265-269.